NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Price, News & Analysis $11.15 +0.03 (+0.27%) Closing price 04:00 PM EasternExtended Trading$11.39 +0.24 (+2.14%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Assembly Biosciences Stock (NASDAQ:ASMB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Assembly Biosciences alerts:Sign Up Key Stats Today's Range$10.80▼$11.8950-Day Range$11.12▼$17.4952-Week Range$10.89▼$19.93Volume20,355 shsAverage Volume24,349 shsMarket Capitalization$70.87 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingModerate Buy Company OverviewAssembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Read More… Remove Ads Assembly Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreASMB MarketRank™: Assembly Biosciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 231st out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAssembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAssembly Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Assembly Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Assembly Biosciences are expected to decrease in the coming year, from ($6.87) to ($7.64) per share.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Assembly Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.51% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently increased by 25.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.71 Percentage of Shares Shorted0.51% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently increased by 25.55%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.51 News SentimentAssembly Biosciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Assembly Biosciences this week, compared to 10 articles on an average week.Search InterestOnly 1 people have searched for ASMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,983.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Assembly Biosciences is held by insiders.Percentage Held by InstitutionsOnly 19.92% of the stock of Assembly Biosciences is held by institutions.Read more about Assembly Biosciences' insider trading history. Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ASMB Stock News HeadlinesShort Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Expands By 25.5%March 7 at 2:51 AM | americanbankingnews.comIs Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently?March 4, 2025 | insidermonkey.comTrump’s Tariff Horrors (your golden opportunity)With new tariffs on the way, millions of Americans are having nightmares about how much they'll have to spend. But here's the secret they're not talking about… A historic $72 trillion wealth transfer is already underway and it's creating a tidal wave of opportunity for people who know what to do.March 10, 2025 | Awesomely, LLC (Ad)Assembly Biosciences doses first participant in Phase 1a study of ABI-6250February 26, 2025 | markets.businessinsider.comAssembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta VirusFebruary 26, 2025 | globenewswire.comAssembly Biosciences reports positive Phase 1a results in genital herpesFebruary 20, 2025 | markets.businessinsider.comAssembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital HerpesFebruary 20, 2025 | globenewswire.comH.C. Wainwright stays Neutral on Assembly Biosciences after ABI-4334 dataDecember 27, 2024 | markets.businessinsider.comSee More Headlines ASMB Stock Analysis - Frequently Asked Questions How have ASMB shares performed this year? Assembly Biosciences' stock was trading at $15.78 on January 1st, 2025. Since then, ASMB stock has decreased by 29.3% and is now trading at $11.15. View the best growth stocks for 2025 here. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, beating the consensus estimate of ($6.84) by $1.92. The biopharmaceutical company had revenue of $6.25 million for the quarter. Assembly Biosciences had a negative trailing twelve-month return on equity of 121.46% and a negative net margin of 144.05%. When did Assembly Biosciences' stock split? Assembly Biosciences shares reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Assembly Biosciences' major shareholders? Assembly Biosciences' top institutional shareholders include Gilead Sciences Inc. (34.74%), Renaissance Technologies LLC (1.49%), Peapod Lane Capital LLC (0.99%) and B Group Inc. (0.80%). Insiders that own company stock include Alexander Schornstein, John G Mchutchison, Jason A Okazaki, Nicole S White, Michael P Samar, William E Iv Delaney, Michael Houghton, Jeanette M Bjorkquist and Luisa M Stamm. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings11/04/2021Today3/10/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASMB CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees100Year Founded2005Price Target and Rating Average Stock Price Target$35.00 High Stock Price Target$35.00 Low Stock Price Target$35.00 Potential Upside/Downside+212.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,230,000.00 Net Margins-144.05% Pretax Margin-142.50% Return on Equity-121.46% Return on Assets-34.56% Debt Debt-to-Equity RatioN/A Current Ratio2.36 Quick Ratio2.36 Sales & Book Value Annual Sales$28.33 million Price / Sales2.51 Cash FlowN/A Price / Cash FlowN/A Book Value$7.50 per share Price / Book1.49Miscellaneous Outstanding Shares6,356,000Free Float6,032,000Market Cap$71.19 million OptionableOptionable Beta0.62 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ASMB) was last updated on 3/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrumps Tariffs Are Fueling This (collect your share)Trump's new tariffs are shaking up the economy—raising prices, disrupting industries, and forcing businesses t...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.